Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories
- 1 April 2004
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 5 (1) , 52-58
- https://doi.org/10.3816/cbc.2004.n.010
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Mechanism of action of anti-HER2 monoclonal antibodiesAnnals of Oncology, 2001
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNature Medicine, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene, 1998
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.Journal of Clinical Oncology, 1993
- Humanization of an anti-p185HER2 antibody for human cancer therapy.Proceedings of the National Academy of Sciences, 1992
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987